Idarubicin HCl

Anthracycline and daunorubicin analog,topoisomerase inhibitor CAS# 57852-57-0

Idarubicin HCl

Catalog No. BCC1194----Order now to get a substantial discount!

Product Name & Size Price Stock
Idarubicin HCl: 5mg $46 In Stock
Idarubicin HCl: 10mg Please Inquire In Stock
Idarubicin HCl: 20mg Please Inquire Please Inquire
Idarubicin HCl: 50mg Please Inquire Please Inquire
Idarubicin HCl: 100mg Please Inquire Please Inquire
Idarubicin HCl: 200mg Please Inquire Please Inquire
Idarubicin HCl: 500mg Please Inquire Please Inquire
Idarubicin HCl: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Idarubicin HCl

Number of papers citing our products

Chemical structure

Idarubicin HCl

3D structure

Chemical Properties of Idarubicin HCl

Cas No. 57852-57-0 SDF Download SDF
PubChem ID 636362 Appearance Powder
Formula C26H28ClNO9 M.Wt 533.95
Type of Compound N/A Storage Desiccate at -20°C
Synonyms 4-Demethoxydaunorubicin hydrochloride
Solubility DMSO : ≥ 50 mg/mL (93.64 mM)
H2O : 6.67 mg/mL (12.49 mM; Need ultrasonic)
*"≥" means soluble, but saturation unknown.
Chemical Name idarubicin hydrochloride
SMILES C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5ccccc5C4=O)O)(C(=O)C)O)N)O.Cl
Standard InChIKey JVHPTYWUBOQMBP-NSESVTCLSA-N
Standard InChI InChI=1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10?,15?,16-,17?,21?,26-;/m0./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Idarubicin HCl

DescriptionIdarubicin hydrochloride is an anthracycline antibiotic in the treatment of leukaemia and a DNA topoisomerase II inhibitor.In Vitro:The IC50 of idarubicin is 3.3±0.4 ng/mL on MCF-7 monolayers and 7.9±1.1 ng/mL in multicellular spheroids[1]. Idarubicin has shown a greater cytotoxicity than daunorubicin or doxorubicin in various in vitro systems. This has been attributed to a better ability of idarubicin to induce the formation of topoisomerase II -mediated DNA breaks[2].Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively[3]. Idarubicin produces a concentration-dependent reduction in cell growth, with an IC50 value of approximately 0.01 μM. Idarubicin produced a concentration-dependent inhibition of DNA synthesis[4].

References:
[1]. Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7. [2]. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88. [3]. Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70. [4]. Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361-

Protocol

Cell Assay [1]
Stock solutions of idarubicin hydrochloride is dissolved in distilled water (1 mg/mL). MCF-7 monolayer are exposed to idarubicin or its metabolite idarubicinol at 0.01, 0.1, 1, 10, 100, and 1000 ng/mL for 24 hours. Multicellular spheroids are exposed to the same range of idarubicin and idarubicinol concentration as monolayers (0.01-1000 ng/mL) for 24 h and, in separate experiments, at the drug concentration of 100 ng/mL for 6, 12, 24 and 48 h. The inhibition of cell proliferation is determined by counting the viable cells with an hemocytometer. Results are expressed as percentage of cell survival vs. control cultures[1].

References:
[1]. Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7. [2]. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88. [3]. Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70. [4]. Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361-

Idarubicin HCl Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Idarubicin HCl Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Idarubicin HCl

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.8728 mL 9.3642 mL 18.7283 mL 37.4567 mL 46.8209 mL
5 mM 0.3746 mL 1.8728 mL 3.7457 mL 7.4913 mL 9.3642 mL
10 mM 0.1873 mL 0.9364 mL 1.8728 mL 3.7457 mL 4.6821 mL
50 mM 0.0375 mL 0.1873 mL 0.3746 mL 0.7491 mL 0.9364 mL
100 mM 0.0187 mL 0.0936 mL 0.1873 mL 0.3746 mL 0.4682 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Idarubicin HCl

Idarubicin is an inhibitor of DNA topoisomerase II [1].

Idarubicin is a synthetic anthracycline anticancer drug widely used in the treatment of acute myelogenous leukemia and some other hematological malignancies. It can be bioactivated by NADPH-cytochrome P450 reductase with resulting formation of single-strand breaks in DNA. This is the mechanism of Idarubicin ‘s antitumor effect [2].

Idarubicin is developed in an attempt to reduce the cardiotoxicity and enhance the therapeutic efficacy of the parent compound. Unlike the parent compound, Idarubicin can be given orally and has a better therapeutic index with respect to cardiotoxicity. Idarubicin has been shown to be an effective anti-leukemic agent in children and adults [3].

References:
[1] H. Dorota Halicka, M. Fevzi Ozkaynak, Oya Levendoglu-Tugal, Claudio Sandoval , Karen Seiter, Malgorzata Kajstura, Frank Traganos, Somasunadaram Jayabose, and Zbigniew Darzynkiewicz. DNA damage response as a biomarker in treatment of leukemias. Cell Cycle. 2009, 8(11): 1720–1724.
[2] Haydar Çelik and Emel Arinç. Evaluation of the Protective Effects of Quercetin, Rutin, Resveratrol, Naringenin and Trolox Against Idarubicin-Induced DNA Damage. J Pharm Pharmaceut Sci. 2010, 13(2): 231 – 241.
[3] Ching-Hon Pui, Siebold S. N. de Graaf, Lois W. Dow, John H. Rodman, William E. Evans, Bruce S. Alpert and Sharon B. Murphy. Phase I Clinical Trial of Orally Administered 4-Demethoxydaunorubicin (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia. Cancer Research. 1988, 48: 5348-5352.

Featured Products
New Products
 

References on Idarubicin HCl

Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study.[Pubmed:3456281]

Cancer Chemother Pharmacol. 1986;16(2):107-15.

The disposition of [14-14C]4-demethoxydaunorubicin HCl ([14-14C]Idarubicin HCl, [14C]IDR) and of [14-14C]daunorubicin HCl ([14C]DNR) was studied in male Sprague Dawley rats. [14C]IDR was administered either IV at 0.25 mg/kg body weight or PO at 1 mg/kg body weight, whereas [14C]DNR was dosed IV at 1 mg/kg body weight. The main elimination route for both compounds was the bile, fecal excretion representing 0.75-0.8 times the total dose at 72 h. Radioactivity due to [14C]IDR-derived species is released by the tissues at a slower rate than activity derived from [14C]DNR. After IV treatment comparable plasma levels are obtained, but tissue radioactivity is markedly lower with [14C]IDR, in keeping with the lower dosage. The ratio of plasma to tissue radioactivity is even higher in animals treated PO with [14C]IDR, because of the more extensive metabolism after this route of administration. The 13-dihydro derivatives of both [14C]IDR and [14C]DNR are the main metabolites in tissues, but in the case of the former, products of phase II reactions become more important at later times in liver and kidney and in excreta.

Description

Idarubicin hydrochloride is an anthracycline antileukemic drug. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.

Keywords:

Idarubicin HCl,57852-57-0,4-Demethoxydaunorubicin hydrochloride,Natural Products,Topoisomerase, buy Idarubicin HCl , Idarubicin HCl supplier , purchase Idarubicin HCl , Idarubicin HCl cost , Idarubicin HCl manufacturer , order Idarubicin HCl , high purity Idarubicin HCl

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: